Lyra Therapeutics, Inc.

No Longer Reporting

The company has not filed an annual or quarterly report since its FY2025 10-K, filed Mar 31, 2026. Its latest SEC filing is a 4 from May 15, 2026.

The sections below describe the company as of the FY2025 annual report.

FY2025 revenue

Operating income, FY2025

−7794% of revenue

▼ −68% (Loss) vs FY2024 (−$96.3M, −6281%)

Net income, FY2025

−7261% of revenue

▼ −69% (Loss) vs FY2024 (−$93.4M, −6089%)

Free cash flow, FY2025

−7280% of revenue

▼ −60% (Loss) vs FY2024 (−$72.3M, −4716%)

Grew. Revenue grew 40% in 4 years, from $285K in FY2021 to $398K in FY2025, about 9% a year.

Comments